CTOs on the Move

Talaris Therapeutics

www.talaristx.com

 
Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.talaristx.com
  • 201 East Jefferson Street Suite 110B
    Louisville, KY USA 40202
  • Phone: 502.569.1059

Executives

Name Title Contact Details
Michael Zdanowski
Chief Technology Officer Profile
Eric Gornstein
Head of New Product Planning Profile
Carlos Yuraszeck
Senior Vice President of Technical Operations Profile

Funding

Talaris Therapeutics raised 4/18/2019 on 05/03/2019

Similar Companies

ChromaCode

ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina, Google[x], Luminex, and Caltech.

Aptus Genomics

Aptus Genomics is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

5 hour energy

5 hour energy is a Farmington, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accent Therapeutics

Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.

IMIDomics

IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d`Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.